ArticleBritish journal of haematology2026
Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Classical cytogenetics (CC) encompassing fluorescence in situ hybridisation (FISH) and karyotype remains central to the diagnostic work-up of non-Hodgkin lymphoma (NHL). However, karyotype is limited by restricted access to fresh tumour tissue and low resolution, while FISH provides targeted information. Optical genome mapping (OGM) has emerged as a genome-wide, high-resolution approach capable of detecting both translocations and copy number variations in a single assay. To assess its feasibility and diagnostic performance in routine practice, we prospectively compared OGM to CC in 105 patients with NHL. OGM was technically feasible in both fresh and frozen tissue specimens. Among 511 cytogenetic abnormalities (CAs) directly compared, 91.1% were concordant between the two methods. Using the low allele fraction guided assembly pipeline, OGM identified all 77 immunoglobulin loci rearrangements, with a sensitivity threshold of 5%. Overall, OGM detected diagnostically relevant CAs in 99/105 patients (94.2%). OGM outperformed CC in 10/105 patients (9.5%), revealing cryptic rearrangements involving major target genes (MYC, BCL2 and BCL6) as well as diagnostically relevant CAs in cases with uncertain diagnoses or non-informative karyotypes. In conclusion, OGM demonstrated feasibility in routine practice and superior diagnostic performance compared with CC, supporting its integration into the standard genetic work-up of NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.